Literature DB >> 16015482

Choline kinase: a novel target for antitumor drugs.

J C Lacal1.   

Abstract

Malignant cells are characterized by the accumulation of genetic alterations, which result in the disregulation of signal transduction pathways that control proliferation, differentiation and apoptosis. The identification of the molecular components involved in these aberrant processes is necessary for the development of chemotherapeutic interventions to restore or selectively destroy the transformed cells. Discovery of new chemotherapeutic agents is probably one of the most reliable ways to improve our success against cancer, and intelligent drug design is a key factor to achieve this goal. Thus, the identification of novel targets for anticancer drug discovery is needed. This review provides evidence to support choline kinase as one such target.

Entities:  

Year:  2001        PMID: 16015482

Source DB:  PubMed          Journal:  IDrugs        ISSN: 1369-7056


  33 in total

1.  Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM.

Authors:  Radhika Srinivasan; Joanna J Phillips; Scott R Vandenberg; Mei-Yin C Polley; Gabriela Bourne; Alvin Au; Andrea Pirzkall; Soonmee Cha; Susan M Chang; Sarah J Nelson
Journal:  Neuro Oncol       Date:  2010-07-20       Impact factor: 12.300

2.  Silencing of the glycerophosphocholine phosphodiesterase GDPD5 alters the phospholipid metabolite profile in a breast cancer model in vivo as monitored by (31) P MRS.

Authors:  J P Wijnen; L Jiang; T R Greenwood; M Cheng; M Döpkens; M D Cao; Z M Bhujwalla; B Krishnamachary; D W J Klomp; K Glunde
Journal:  NMR Biomed       Date:  2014-04-24       Impact factor: 4.044

Review 3.  Metabolic effects of signal transduction inhibition in cancer assessed by magnetic resonance spectroscopy.

Authors:  Siver Andreas Moestue; Olav Engebraaten; Ingrid Susann Gribbestad
Journal:  Mol Oncol       Date:  2011-04-23       Impact factor: 6.603

4.  Choline kinase beta is required for normal endochondral bone formation.

Authors:  Zhuo Li; Gengshu Wu; Roger B Sher; Zohreh Khavandgar; Martin Hermansson; Gregory A Cox; Michael R Doschak; Monzur Murshed; Frank Beier; Dennis E Vance
Journal:  Biochim Biophys Acta       Date:  2014-03-14

5.  Choline kinase inhibition in rheumatoid arthritis.

Authors:  M Guma; E Sanchez-Lopez; A Lodi; R Garcia-Carbonell; S Tiziani; M Karin; J C Lacal; G S Firestein
Journal:  Ann Rheum Dis       Date:  2014-10-01       Impact factor: 19.103

6.  Antiplasmodial activity and mechanism of action of RSM-932A, a promising synergistic inhibitor of Plasmodium falciparum choline kinase.

Authors:  Tahl Zimmerman; Carlos Moneriz; Amalia Diez; José Manuel Bautista; Teresa Gómez Del Pulgar; Arancha Cebrián; Juan Carlos Lacal
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

7.  Phospholipase D1 and choline kinase-α are interactive targets in breast cancer.

Authors:  Mayur Gadiya; Noriko Mori; Maria D Cao; Yelena Mironchik; Samata Kakkad; Ingrid S Gribbestad; Kristine Glunde; Balaji Krishnamachary; Zaver M Bhujwalla
Journal:  Cancer Biol Ther       Date:  2014-02-20       Impact factor: 4.742

8.  Nuclear magnetic resonance detects phosphoinositide 3-kinase/Akt-independent traits common to pluripotent murine embryonic stem cells and their malignant counterparts.

Authors:  Hanna M Romanska; Stefano Tiziani; Rachael C Howe; Ulrich L Günther; Zulfiqar Gulzar; El-Nasir Lalani
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

9.  A critical role for choline kinase-alpha in the aggressiveness of bladder carcinomas.

Authors:  E Hernando; J Sarmentero-Estrada; T Koppie; C Belda-Iniesta; V Ramírez de Molina; P Cejas; C Ozu; C Le; J J Sánchez; M González-Barón; J Koutcher; C Cordón-Cardó; B H Bochner; J C Lacal; A Ramírez de Molina
Journal:  Oncogene       Date:  2009-05-18       Impact factor: 9.867

10.  Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatment.

Authors:  David Gallego-Ortega; Ana Ramirez de Molina; Maria Angeles Ramos; Fatima Valdes-Mora; Maria Gonzalez Barderas; Jacinto Sarmentero-Estrada; Juan Carlos Lacal
Journal:  PLoS One       Date:  2009-11-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.